Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease

Table 2 Effect of extraintestinal manifestations on serum bile acids and conjugates in UC cohorts (nmol/L)

BA class	BA/BA-conjugate	Control	No EM	Arthralgia/arthritis	Hepatobiliary diseases
Primary	CA	62.5	67.5	88.5	59.0
	TCA	23.6	0.0	0.0	67.9bc
	GCA	383.5	360.0	408.5	722.5ab
	CDCA	196.5	37.5	175.5	252.0
	TCDCA	230.5	140.0a	92.5a	163.0c
	GCDCA	1446.0	1327.0	1281.5	2403.0bc
Secondary	DCA	239.8	78.0a	28.0a	62.5a
	TDCA	48.2	0.0a	0.0a	0.0a
	GDCA	38.6	82.2a	14.0a	131.7c
	LCA	15.0	8.0a	6.1a	18.0bc
	TLCA	0.0	0.0a	0.0a	0.0
	GLCA1	17.4	2.0a	0.0	6.5
	UDCA	28.5	18.0a	7.0ab	131.5bc
	TUDCA	0.0	0.0	0.0ab	30.9abc
	GUDCA1	137.9	96.5	54.1	75.1
Tertiary	HDCA	0.0	9.5a	8.0a	28.0a
	THDCA	0.0	0.0a	0.0	0.0
	GHDCA1	0.0	0.0	0.0	0.0

Control: n = 310; No EM: n = 50, n = 21¹; Arthralgia/arthritis: n = 30, n = 7¹; Hepatobiliary diseases: n = 16, n = 6¹. Data expressed as medians.

^aP < 0.05 vs control,

^bP < 0.05 vs no EM,

^cP < 0.05 vs arthralgia/arthritis (Mann-Whitney U test).